Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders

被引:3
作者
Gorniak, Agata [1 ]
Czapor-Irzabek, Hanna [1 ]
Zlocinska, Adrianna [1 ]
Gawin-Mikolajewicz, Agnieszka [2 ]
Karolewicz, Bozena [2 ]
机构
[1] Wroclaw Med Univ, Lab Elemental Anal & Struct Res, Borowska 211A, PL-50556 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Drug Form Technol, Borowska 211A, PL-50556 Wroclaw, Poland
关键词
simvastatin; fenofibrate; solid dispersion; eutectic; dissolution improvement; dyslipidemia; fixed-dose combination; HIGH-RISK PATIENTS; COMBINATION; DISSOLUTION; IMPROVE; SAFETY; FORMS;
D O I
10.3390/pharmaceutics15020603
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The combination of statins and fibrates in the treatment of lipid abnormalities effectively regulates individual lipid fraction levels. In this study, the screening and assessment of the physicochemical properties of simvastatin-fenofibrate solid dispersions were performed. Fenofibrate and simvastatin were processed using the kneading method in different weight ratios, and the resulting solid dispersions were assessed using differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), contact angle, as well as dissolution tests. The obtained results confirmed the formation of a simple eutectic phase diagram, with a eutectic point containing 79 wt% fenofibrate and 21 wt% simvastatin, lack of chemical interactions between the ingredients, and simvastatin impact on improving fenofibrate dissolution profile, due to the formation of crystalline solid dispersions by the kneading method.
引用
收藏
页数:15
相关论文
共 30 条
[1]   Solubility of simvastatin: A theoretical and experimental study [J].
Aceves-Hernandez, Juan M. ;
Hinojosa-Torres, Jaime ;
Nicolas-Vazquez, Ines ;
Miranda Ruvalcaba, Rene ;
Lima Garcia, Rosa Maria .
JOURNAL OF MOLECULAR STRUCTURE, 2011, 995 (1-3) :41-50
[2]   Development of a Discriminative and Biorelevant Dissolution Test Method for Atorvastatin/Fenofibrate Combination with Appliance of Derivative Spectrophotometry [J].
Anumolu, Panukumar Durga ;
Gurrala, Sunitha ;
Venkata Satya, Subrahmanyam Chavali ;
Polisetty, Santoshi Vani ;
Ravindran, Anjana ;
Achanta, Radhagayathri .
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 16 (01) :62-68
[3]   Fixed-dose combinations improve medication compliance: A meta-analysis [J].
Bangalore, Sripal ;
Kamalakkannan, Gayathri ;
Parkar, Sanobar ;
Messerli, Franz H. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (08) :713-719
[4]   Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs [J].
Bazzo, Giovana Carolina ;
Pezzini, Bianca Ramos ;
Stulzer, Hellen Karine .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 588
[5]   Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy Implications for Risk Assessment, Prevention and Treatment [J].
Chatzizisis, Yiannis S. ;
Koskinas, Konstantinos C. ;
Misirli, Gesthimani ;
Vaklavas, Christos ;
Hatzitolios, Apostolos ;
Giannoglou, George D. .
DRUG SAFETY, 2010, 33 (03) :171-187
[6]   Dyslipidemia Management for Elderly People with Metabolic Syndrome: A Mini-Review [J].
Chen, Chun-Yen ;
Lee, Chun-Wei ;
Chien, Shih-Chieh ;
Su, Min-I. ;
Lin, Shu-I. ;
Cheng, Chung-Wei ;
Hung, Ta-Chuan ;
Yeh, Hung-I. .
INTERNATIONAL JOURNAL OF GERONTOLOGY, 2018, 12 (01) :7-11
[7]   Metabolic syndrome and subsequent risk of type 2 diabetes and cardiovascular disease in elderly women: Challenging the current definition [J].
Dragsbaek, Katrine ;
Neergaard, Jesper S. ;
Laursen, Janne M. ;
Hansen, Henrik B. ;
Christiansen, Claus ;
Beck-Nielsen, Henning ;
Karsdal, Morten A. ;
Brix, Susanne ;
Henriksen, Kim .
MEDICINE, 2016, 95 (36)
[8]  
European Medicines Agency, CHOL EPAR SUMM PUBL
[9]   Pravastatin and fenofibrate in combination (Pravafenix (R)) for the treatment of high-risk patients with mixed hyperlipidemia [J].
Farnier, Michel .
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (05) :565-575
[10]   Safety considerations with fenofibrate/simvastatin combination [J].
Filippatos, Theodosios D. ;
Elisaf, Moses S. .
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (09) :1481-1493